1. ORION- 1
Impact of a 1- or 2-dose starting regimen of inclisiran, a novel siRNA inhibitor to PCSK9 on time averaged LDL-C reductions over 1 year
Kausik K Ray, Ulf Landmesser, Lawrence A Leiter, David Kallend, Peter Wijngaard, R Scott Wright, and John JP Kastelein
On behalf of the ORION-1 investigators

2. 2

3. Disclosure s Research grants: Amgen, Sanofi, Regeneron, MSD, Pfizer
Consultancy:
Amgen, Sanofi, Regeneron, MSD, Pfizer, Astra Zeneca, Lilly, Medicines Company, Kowa, IONIS, Takeda, Novo Nordisk, Boehringer Ingelheim, Esperion, Cipla, Algorithm, Abbvie, Resverlogix, Cerenis 3

4. Background LDL-C variability common, associated with worse outcomes
Six month percent change in LDL-C among statin users from starting level1
Increase in death, CV outcomes with each 1 standard deviation of LDL-C variability2 60
23% 40
% change in LDL-C from BL
17%
16% 20
11%
10%
-20
-40
Death
Stroke
Any coronary event
Any CV event MI
-60
1. Ray KK et al. N Engl J Med 2017; 376:
2. Bangalore S et al. JACC 2015; 65: 4

5. Background PCSK9 inhibition reduces LDL-C and ASCVD1
PCSK9 monoclonal antibody treatment requires injections per year1 Adherence unlikely to show substantial improvement over statins2 Limitations are most relevant in high risk patients needing lifelong therapy
In the future can we do better?
Sabatine MS et al. N Engl J Med 2017; 376:
Hines D et al. ACC 2017 abstract # 5

6. Background RNAi is an intrinsic process for inhibiting mRNA
Synthetic siRNA
dicer
dsRNA
Cleavage
Natural process of RNA interference
Strand separation
Targeted gene silencing
RISC
Complementary pairing
mRNA
Cleavage
mRNA
degradation 6

7. Background GalNAc-siRNA conjugates facilitate rapid hepatic uptake
Asialoglycoprotein receptor (ASGPR)
Highly expressed in hepatocytes only
High rate of uptake
GalNAc-siRNA inclisiran conjugate
Clathrin-coated pit
ASGPR (pH>5)
GalNA c3
Recycling ASGPR
Clathrin-coated vesicle
Inclisiran
siRNA conjugated to N-acetylgalactosamine
Subcutaneous administration
Targeted delivery to hepatocytes
Hepatocyte
cytoplasm
Endosome 7

8. Methods ORION 1 trial design
Screened (696)
Stratified by country and Rx
Randomized (501)
One dose start
Two dose start
Placebo
N=65
200 mg
N=60
300 mg
N=61*
500 mg
N=65*
Placebo
N=62
100 mg
N=61*
200 mg
N=62*
300 mg
N=61
Treated (497)
Day 1
Day 14
Day 30
Study drug given 1st follow-up visit
Monthly follow-up visits
Day 1
Day 14
Day 30
Study drug given 1st follow-up visit
Monthly follow-up visits
Day 90
Day 90
Study drug given
Day 180
Primary evaluation
Day 180
Primary evaluation
Day 210
End of study visit
Day 210
End of study visit
Completed (483)
Day 360
Extended follow-up
Day 360
Extended follow-up 8

9. Patients High-risk CV patients, balanced by randomization
One dose starting regimen
Two dose starting regimen
Placebo
N=65
Inclisiran
N=186
N=62
N=184
Age
Mean years 62 63 64
Male sex %
64.6
67.7
53.2
66.3
Prior ASCVD
69.2
67.9
74.2
68.3
Statin Rx %
70.3
74.4
77.0
70.2
LDL-C
Mean mg/dL
128.5
125.9
125.2
133.0
Non-HDL-C
157.8
156.5
157.1
165.6
Apo-B
102.4
103.2
104.6
107.7
Lipoprotein(a)
Median nmol/L
27.0
34.0
50.5
40.0
PCSK9
Mean ng/mL
404.7
428.7
431.3
416.2 9

10. Safety No safety concerns in study with follow up to Day 360
Similar overall adverse event profile and incidence for inclisiran and placebo No LFT elevations considered related to investigational drug
Similar incidence of transient transaminase increases in randomized groups
No difference in incidence of myalgias or CPK enzyme elevation
One clinically relevant case of myonecrosis on placebo
No deaths related to drug administration
Two previously reported deaths1 >100 days, related to underlying disease
1: Patient A: History of CHD, MI and PCI died of a fatal MI on Day 104 of the study. (500mg x1 dose)
Patient B: Developed complications of aortic aneurysm surgery including an aorto-esophageal fistula requiring esophagectomy, leading to infection of the prosthesis, sepsis, and stroke, culminating in death on Day 198 of the study. Patient also had AF, chronic renal failure, emphysema, HT and obesity. (200mg x2 doses) 10

11. Efficacy: One dose starting regimen Robust, sustained LDL-C reductions – 300 mg optimal10
Mean percent change (±95% CI)
Placebo
-10
200mg
P-value for all comparisons to placebo <0.0001
-20
300 mg
-30
500 mg
-40
-50
-60 30 60 90
120
Days from first injection
270
300
330
360 11

12. Efficacy: Two dose starting regimen Robust, sustained LDL-C reductions – optimal start regimen
300 mg x2
55.5% 52.5%
300 mg x2
31.4% 10
Mean percent change (±95% CI)
Placebo
100 mg
-10
P-value for all comparisons to placebo <0.0001
-20
200 mg
-30
300 mg
-40
-50
-60 30 60 90
120
Days from first injection
270
300
330
360 12

13. Sustained LDL-C lowering effects over time Time-averaged reduction from Day 1 to Day 360
One dose starting regimen
Two dose starting regimen
Tim e a d j u s t e d p e r c e n t c h a n g e i n L D L - C t o D a y
Inclisiran mg
Inclisiran mg
Inclisiran mg
Inclisiran mg
Inclisiran mg
Inclisiran mg
-30%
-30%
-37%
-39%
-40%
-46% 13

14. Inclisiran dose 300mg sc Day 1, 90, 270 and 6- monthly Sustained >50% reduction in LDL-C for 6- months
One dose starting regimen (300 mg)
Two dose starting regimen (300 mg)
% Change in LDL-C from Baseline 10 10
Time adjusted LDL-C for 6 months = 41%
Time adjusted LDL-C for 6 months = 51%
-10
-10
-20
-20
-30
-30 Q3 Q3
-40
-40
Mean Median
Mean Median
-50
-50
-60
-60 Q1 Q1
-70
-70
-80
-80
Day 90
Day 270
Day 90
Day 270 14

15. Efficacy: Day 360 LDL-C reduction in mg/dL Individual patient responses
One dose starting regimen (N = 112)
Two dose starting regimen (N = 142)
200 mg
N = 30
300m g N = 38
500 mg
N = 44
100 mg
N = 41
200 mg
N = 48
300 mg
N = 53 40 40
-40
-40
-80
-80
-120
-120
-160
-160
-200
-200 15

16. Conclusions Robust LDL-C with 6 monthly inclisiran dosing
Safety
By day 360, patients are predictably returning towards baseline
No safety signals at 1 year (>250 patient-years of observation)
Dose and dose frequency
300 mg given s.c. at Day 1 and Day 90 represents the optimal starting dose
300 mg given s.c. at Day 270 then every 180 days is the maintenance dose
This dosing schedule provides robust and consistent LDL-C lowering
46% time-averaged reduction over 12 months
51% time-averaged reduction over 6-monthly dosing interval
Minimal within-patient variability in LDL-C reduction over time 16

17. Implications Inclisiran has moved into Phase III
LDL-C lowering trials underway
3,000 subjects with ASCVD/ risk equivalents (ORION-10, -11)
400 subjects with HeFH (ORION-9)
60 subjects with HoFH (ORION-5)
Parallel cardiovascular outcomes trial in preparation
15,000 subjects with high risk ASCVD (ORION-4) 17

18. Backu p

19. Safety No safety concerns in follow up to Day 360
Safety population
One dose starting regimen
Placebo Inclisiran
Two dose starting regimen
N=65 N=186
N=62 N=184 n
(%)
Any TEAE 51
(78.5)
155
(81.3) 51
(82.3)
153
(83.2)
Serious 3
(4.6) 30
(16.1) 7
(11.3) 31
(16.8)
Severe 2
(3.1) 18
(9.7) 22
(12.0)
Related 12
(18.5) 39
(21.0) 19
(30.6) 52
(28.3)
AE discontinuation 1
(1.6)
(0.5)
Injection site reaction
(3.8)
(6.5)
TEAEs (treatment emergent adverse events) - similar incidence placebo vs inclisiran:
One dose starting regimen: Nasopharyngitis, myalgia, back pain, cough, arthralgia, headache Two dose starting regimen: Myalgia, headache, diarrhea, nasopharyngitis, arthralgia, back pain 19